The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Feasibility of triweekly docetaxel-based chemotherapy for elderly patients (age 75 and older) with castration-resistant prostate cancer.
N. Takaha
No relevant relationships to disclose
T. Iwata
No relevant relationships to disclose
T. Nakamura
No relevant relationships to disclose
F. Hongo
No relevant relationships to disclose
K. Kamoi
No relevant relationships to disclose
K. Okihara
No relevant relationships to disclose
A. Kawauchi
No relevant relationships to disclose
T. Miki
No relevant relationships to disclose